The correlation of expression of VEGF and EGFR with SUV of 18FDG-PET-CT in non-small cell lung cancer

Wspolczesna Onkologia

Volumn 18, Issue 5, 2014, Pages 334-339

  Liu, Xiguang ^a   Zhang, Hongjun ^a   Yu, Xiaoyun ^a   Song, Tingting ^a   Huang, Peng ^a   Wang, Haichao ^a   Song, Shan Ai ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; VASCULOTROPIN;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIOLOGICAL PARAMETERS; STANDARDISED UPTAKE VALUE; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

EID: 84918833211     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.45308     Document Type: Article

References (21)

1. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database. J Clin Oncol 2006; 24: 384S.
2. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83: 355-67.
3. Carney DN. Lung cancer-time to move on from chemotherapy. N Engl J Med 2002; 346: 126-8.
4. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 1794-801.
5. Visbal AL, Williams BA, Nichols FC 3rd, et al. Gender differences in non-small cell lung cancer survival: an analysis of 4, 618 patients diagnosed between 1997-2002. Ann Thorac Surg 2004; 78: 209-15.
6. Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright CD. Data from The Society of Thoracic Surgeons General Thoracic surgery database: the sergical management of primary lung tumors. J Thorac Cardiovasc Surg 2008; 135: 247-52.
7. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinnical practice guidelines (2nd edition). Chest 2007; 132: 234S-42S.
8. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: updated 2003. J Clin Oncol 2004; 22: 330-53.
9. Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop WJ. Estimating the need for radio-therapy for lung cancer: an evidence based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001; 49: 973-85.
10. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-62.
11. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227-34.
12. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006; 24: 2158-63.
13. Port JL, Andrade RS, Levin MA, Korst RJ, Lee PC, Becker DE, Altorki NK. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg 2005; 130: 1611-5
14. Yang JJ, Wu YL, Yan J. A comparative study of 18FDG-PET and CT on diagnosing mediastinal lymph nodes in non-small cell lung cancer. J Evidence-Based Med 2003; 3: 132-41.
15. De Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007; 32: 1-8.
16. Yang JJ, Wu YL, Xu WP. 18FDG-PET evaluation of the objective respons in advanced non-small cell lung cancer. Clin Cancer Res 2007; 19: 461-3.
17. Sunaga N, Oriuchi N, Kaira K, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008; 59: 203-10.
18. de Jong WK, van der Heijden HF, Pruim J, Dalesio O, Oyen WJ, Groen HJ. Prognostic value of different metabolic measurements with fluorine-18 fluomdeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study. J Thorac Oncol 2007; 2: 1007-12.
19. Giraud P, Elles S, Helfre S, et al. Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. Radiother Oncol 2002; 62: 27-36.
20. Steenbakkers RJ, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys 2006; 64: 435-48.
21. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-50.